[go: up one dir, main page]

AU2002211517A1 - Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits - Google Patents

Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits

Info

Publication number
AU2002211517A1
AU2002211517A1 AU2002211517A AU1151702A AU2002211517A1 AU 2002211517 A1 AU2002211517 A1 AU 2002211517A1 AU 2002211517 A AU2002211517 A AU 2002211517A AU 1151702 A AU1151702 A AU 1151702A AU 2002211517 A1 AU2002211517 A1 AU 2002211517A1
Authority
AU
Australia
Prior art keywords
detection
magnetic resonance
resonance imaging
imaging agents
amyloid deposits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211517A
Inventor
Matthew J. Allen
Scott Fraser
Russell E. Jacobs
Thomas J. Meade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology
Original Assignee
California Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology filed Critical California Institute of Technology
Publication of AU2002211517A1 publication Critical patent/AU2002211517A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AU2002211517A 2000-10-04 2001-10-04 Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits Abandoned AU2002211517A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23823100P 2000-10-04 2000-10-04
US60/238,231 2000-10-04
US28537901P 2001-04-20 2001-04-20
US60/285,379 2001-04-20
PCT/US2001/031415 WO2002028441A2 (en) 2000-10-04 2001-10-04 Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits

Publications (1)

Publication Number Publication Date
AU2002211517A1 true AU2002211517A1 (en) 2002-04-15

Family

ID=26931450

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211517A Abandoned AU2002211517A1 (en) 2000-10-04 2001-10-04 Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits

Country Status (3)

Country Link
US (1) US7029655B2 (en)
AU (1) AU2002211517A1 (en)
WO (1) WO2002028441A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
JP4163381B2 (en) 1997-11-17 2008-10-08 カリフォルニア・インスティテュート・オブ・テクノロジー Magnetic resonance contrast agents for the detection of physiological agents
US20040146463A1 (en) * 2000-05-04 2004-07-29 Meade Thomas J. Functional MRI agents for cancer imaging
AU2001285170B2 (en) 2000-08-21 2006-10-26 The Brigham And Women's Hospital, Inc. Methods for diagnosing a neurodegenerative condition
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
PT1420830E (en) * 2001-04-27 2011-04-20 Brigham & Womens Hospital Ocular diagnosis of alzheimer`s disease
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
RU2005126421A (en) * 2003-01-22 2006-02-10 Дзе Дженерал Хоспитал Корпорейшн (Us) AMYLO-BINDING METAL-CHELATING AGENTS
WO2005042461A1 (en) * 2003-10-30 2005-05-12 Dojindo Laboratories Compound with amyloid affinity
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
JP5368099B2 (en) 2005-10-07 2013-12-18 ゲルベ A compound comprising a moiety for recognition of a biological target coupled to a signal moiety capable of complexing with gallium
US20070258907A1 (en) * 2006-04-24 2007-11-08 Davis Mark E Polymer-coated paramagnetic particles
US8337813B2 (en) * 2007-09-14 2012-12-25 Northwestern University Contrast agents
KR100987592B1 (en) 2008-03-10 2010-10-12 경북대학교 산학협력단 RM contrast agent for cancer diagnosis and its manufacturing method
HUE044239T2 (en) 2008-03-27 2019-10-28 Purdue Research Foundation Collagen-binding synthetic peptidoglycans, preparation, and methods of use
US8580231B2 (en) 2008-05-23 2013-11-12 Northwestern University Compositions and methods comprising magnetic resonance contrast agents
US20100029909A1 (en) * 2008-05-23 2010-02-04 Northwestern University Compositions and methods comprising magnetic resonance contrast agents
US20100129290A1 (en) * 2008-11-26 2010-05-27 I.S.T. Corporation Smart contrast agent and detection method for detecting transition metal ions
FR2942227B1 (en) 2009-02-13 2011-04-15 Guerbet Sa USE OF BUFFERS FOR RADIONUCLEID COMPLEXATION
US20130115257A1 (en) * 2010-07-08 2013-05-09 Katholieke Universiteit Leuven Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates
WO2012078647A2 (en) * 2010-12-07 2012-06-14 Steven Verdooner Chemical composition to detect and treat amyloid in a patient's brain and retina
FR2968999B1 (en) 2010-12-20 2013-01-04 Guerbet Sa CHELATE NANOEMULSION FOR MRI
PT2694116T (en) * 2011-04-06 2018-10-12 Univ Texas Lipid-based nanoparticles
CN103491870B (en) * 2011-04-21 2016-12-28 加利福尼亚大学董事会 Functionalized magnetic nanoparticles and their use in imaging amyloid deposits and neurofibrillary tangles
HUE031596T2 (en) 2011-05-24 2017-07-28 Symic Ip Llc Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
FR2980364B1 (en) 2011-09-26 2018-08-31 Guerbet NANOEMULSIONS AND THEIR USE AS CONTRAST AGENTS
NL2007714C2 (en) 2011-11-04 2013-05-08 Academisch Ziekenhuis Leiden Lumc Imaging ligands.
BR112014010879A2 (en) 2012-01-20 2017-06-13 Annapragada Ananth methods and compositions for objectively characterizing medical images
FR3001154B1 (en) 2013-01-23 2015-06-26 Guerbet Sa MAGNETO-EMULSION VECTORIZED
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
WO2014144969A1 (en) 2013-03-15 2014-09-18 Purdue Research Foundation Extracellular matrix-binding synthetic peptidoglycans
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
CA2963941C (en) 2014-10-08 2023-08-01 Texas Children's Hosptial Mri imaging of amyloid plaque using liposomes
US9737698B2 (en) * 2016-01-04 2017-08-22 Givi Topchiashvili Method and system for treating patients with alzheimer disease
AU2018298224B2 (en) 2017-07-07 2024-08-15 Symic Ip, Llc Synthetic bioconjugates
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
CN112735799B (en) * 2020-12-10 2022-12-20 华东理工大学 Novel magnetic material and preparation method thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837169A (en) 1981-07-01 1989-06-06 Eastman Kodak Company Polypyridine Fluorescent labels for immunoassay
US4637988A (en) 1981-07-01 1987-01-20 Eastman Kodak Company Fluorescent labels for immunoassay
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US5188816A (en) 1984-10-18 1993-02-23 Board Of Regents, The University Of Texas System Using polyazamacrocyclic compounds for intracellular measurement of metal ions using MRS
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
EP0247156B1 (en) 1985-11-18 1993-06-23 Access Pharmaceuticals Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US4877872A (en) 1986-06-24 1989-10-31 The University Of Toledo Production and use of dimers of hematoporophyrin, purpurins, chlorines and purpurin- and chlorin-complexes
US5219553A (en) 1986-08-04 1993-06-15 Salutar, Inc. Composition of a n-carboxymethylated tetraazacyclododecane chelating agent, a paramagnetic metal and excess calcium ions for MRI
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
FR2604092B1 (en) 1986-09-19 1990-04-13 Immunotech Sa IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO
US4822594A (en) 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4867963A (en) * 1987-01-29 1989-09-19 Temple University Of The Commonwealth System Of Higher Education Enhancement of NMR imaging of tissue by paramagnetic pyrophosphate contrast agent
US5531978A (en) 1987-07-16 1996-07-02 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
IE61746B1 (en) 1987-07-16 1994-11-30 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
US5162509A (en) 1989-03-06 1992-11-10 Board Of Regents, The University Of Texas System Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5554748A (en) 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5230883A (en) 1989-05-04 1993-07-27 Wisconsin Alumni Research Foundation Method for localization and treatment of tumors using polylysine complexes
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5446145A (en) 1990-01-19 1995-08-29 Nycomed Salutar, Inc. Polychelant compounds
CA2072080A1 (en) 1990-01-19 1991-07-20 Jo Klaveness Chelating compounds
US5095099A (en) 1990-12-10 1992-03-10 E. I. Du Pont De Nemours And Company Fluorescent compounds for absorption and re-emission of radiation
US5310539A (en) 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
WO1992019264A1 (en) 1991-05-01 1992-11-12 University Of New Mexico Biomodulators as universal imaging agents
EP0594640A4 (en) 1991-05-23 1998-06-03 Evan C Unger Liposoluble compounds for magnetic resonance imaging
US5133956A (en) 1991-05-30 1992-07-28 The Dow Chemical Company Radiolabeled metal-binding protein for the treatment of arthritis
US5262532A (en) 1991-07-22 1993-11-16 E.R. Squibb & Sons, Inc. Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US5407657A (en) 1992-09-22 1995-04-18 Unger; Evan C. Hybrid magnetic resonance contrast agents
US5466439A (en) 1992-11-12 1995-11-14 Magnetic Research, Inc. Polymeric contrast enhancing agents for magnetic resonance images
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US5358704A (en) 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents
DK0661279T3 (en) 1993-12-30 2001-07-16 Guerbet Sa Polyaminized ligands, metal complexes, methods for their preparation and diagnostic and therapeutic applications
DE4403789A1 (en) 1994-02-03 1995-08-10 Schering Ag Means for visually marking body tissues
JP3878208B2 (en) 1994-04-08 2007-02-07 ブラッコ インターナショナル ベスローテン フェンノートシャップ Aromatic amide compounds and their chelates
GB9407812D0 (en) 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
IT1269839B (en) 1994-05-26 1997-04-15 Bracco Spa CONJUGATES OF BILIARY ACIDS, THEIR DERIVATIVES WITH METALLIC COMPLEXES AND RELATED USES
US5622821A (en) 1994-06-29 1997-04-22 The Regents Of The University Of California Luminescent lanthanide chelates and methods of use
DE4428874A1 (en) 1994-08-08 1996-02-22 Schering Ag Dimer DTPA derivatives and their metal complexes, pharmaceutical compositions containing these complexes, their use in diagnostics and therapy, and methods for producing the complexes and compositions
TW319763B (en) 1995-02-01 1997-11-11 Epix Medical Inc
US5955605A (en) 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
EP0823894A1 (en) * 1995-05-01 1998-02-18 University Of Pittsburgh Azocompounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US5707605A (en) 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US5980862A (en) 1995-06-02 1999-11-09 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
WO1997021431A1 (en) 1995-12-12 1997-06-19 California Institute Of Technology Cobalt schiff base compounds
IT1283218B1 (en) 1996-03-08 1998-04-16 Bracco Spa POLYKELANTS, THEIR COMPLEXES WITH METALLIC IONS, THEIR PREPARATION AND THEIR USES
PT907379E (en) 1996-04-01 2004-09-30 Epix Medical Inc BIOACTIVATED CONTRACT AGENTS FOR DIAGNOSTIC IMAGIOLOGY
US6054114A (en) * 1996-05-08 2000-04-25 Massachusetts Institute Of Technology Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro
US5900228A (en) * 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
DE69811931T2 (en) 1997-10-27 2003-12-18 Research Corp. Technologies, Inc. MRI AGENTS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
WO2001074374A1 (en) * 2000-04-04 2001-10-11 Mayo Foundation For Medical Education And Research Methods for detecting plaques in vivo

Also Published As

Publication number Publication date
WO2002028441A9 (en) 2003-02-20
US7029655B2 (en) 2006-04-18
US20020098153A1 (en) 2002-07-25
WO2002028441A2 (en) 2002-04-11
WO2002028441A3 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AU2002211517A1 (en) Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
AU2001251150A1 (en) Magnetic resonance imaging with resolution and contrast enhancement
AU1073601A (en) Fullerene contrast agent for magnetic resonance imaging and spectroscopy
EP1310211A4 (en) Magnetic resonance imaging device and method
AU2001229650A1 (en) Vessel delineation in magnetic resonance angiographic images
EP1171032A4 (en) METHODS FOR IN VIVO MAGNETIC RESONANCE IMAGING
AU2002227276A1 (en) Accelerated magnetic resonance imaging
AU2002239655A1 (en) Contrast enhancement agent for magnetic resonance imaging
GB9926918D0 (en) Magnetic resonance imaging
GB9929070D0 (en) Magnetic resonance imaging device
AU2002210847A1 (en) Magnetic resonance imaging device
EP1060706A4 (en) Magnetic resonance imaging device
AU2002235546A1 (en) 4 dimensional magnetic resonance imaging
EP1371327A4 (en) Magnetic resonance imaging apparatus and method
AU2002314794A1 (en) Detection of alzheimer's amyloid by magnetic resonance imaging
AP2002002389A0 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives
GB9927358D0 (en) Endoscope suitable for magnetic resonance imaging
GB9926923D0 (en) Magnetic resonance imaging
ITSV970048A0 (en) PERMANENT MAGNET FOR NUCLEAR MAGNETIC RESONANCE IMAGING DETECTION.
AU3386799A (en) (in vivo) magnetic resonance vascular imaging using laser-polarized gas microbubbles
AU2003219874A1 (en) Electroencephalograph sensor for use with magnetic resonance imaging and methods using such arrangements
AU5085800A (en) Method of magnetic resonance imaging
HUP0202508A3 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
GB9923797D0 (en) Magnetic resonance imaging apparatus
EP1314393A4 (en) Magnet device and magnetic resonance imaging apparatus comprising it